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NMRAbstract An unknown impurity was detected in the telmisartan bulk drug (active pharmaceutical
ingredient – API) using an isocratic reversed-phase high performance liquid chromatography
(HPLC). This impurity was isolated by preparative HPLC. Spectral data of the isolated impurity
were collected. Based on the spectral data deriving from two dimensional nuclear magnetic spec-
troscopy (2D-NMR) and mass spectrometry (MS), the impurity was characterized as ‘‘methyl
40,40-dibromo methyl biphenyl-2-carboxylate’’. The arrived structure was further conﬁrmed by the-
oretical studies.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Telmisartan, chemically 40-[(1,40-dimethyl-20-propyl[2,60-bi-1H-ben-
zimidazol]-10-yl)methyl][1,10-biphenyl]-2-carboxylicacid (Merck In-
dex, 2006) is a member of the family of drugs called angiotensin
receptorblockers(ARBs),whichincludes losartan(Cozaar),valsartan
(Diovan), irbesartan (Avapro), and candesartan (Atacand). ARBsblock the ability of the chemical angiotensin II to constrict or squeeze
arteries andveins.As a result, the arteries andveins enlarge andblood
pressure falls. It is also used for reducing the risk of heart attack,
stroke, or death from cardiovascular causes (Sharma et al., 2002;
Lindholm et al., 2002; Young et al., 2004). It is believed that telmisar-
tan’s dual mode of actionmay provide protective beneﬁts against the
vascular and renal damage causedbydiabetes andcardiovasculardis-
ease (CVD) (Benson et al., 2004; Yusuf et al., 2008). Telmisartanwas
shown to be better tolerated and associated with higher treatment
compliance than ramipril (Engeli et al., 2005).We nowwish to report
the structural characterization of this impurity. The different analyti-
cal techniques reported so far for the determinationof this drug along
with corresponding impurities anddegradationproducts in biological
samples and pharmaceutical formulations are by HPTLC (Potale
et al., 2010; Shahet al., 2007),HPLC(Wankhede et al., 2007;Torreal-
dayetal., 2003;Zhangetal., 2009)andLC–MS/MS(Yanetal., 2008).
The general considerations for the isolation of impurities by
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of unknown impurities observed.
A sample of telmisartan which was synthesized in our lab-
oratory when subjected to HPLC analysis by chromatographic
conditions published in the USP monograph of telmisartan
(USP-NF, 2010), an unknown impurity at 1.59 RRT was ob-
served to a level of 0.09%. As per regulatory guidelines, it is
necessary to know the structure of the impurity to develop a
synthetic process to remove the impurity and also the knowl-
edge of the structure and the source of the new impurity are
necessary in order to develop a more robust synthetic process.
It is therefore, essential to isolate and characterize unidentiﬁed
impurities present in the drug sample. The structure elucida-
tion of this impurity is object of this work.
The sample was taken for the isolation of unknown impu-
rity by using preparative HPLC and the isolated impurity
was characterized by using MS, NMR and IR. To the best
of our knowledge, the impurity detected at 1.59 RRT was
established for the ﬁrst time.
2. Experimental
2.1. Chemicals
HPLC grade acetonitrile, HPLC grade methanol, HPLC grade
monobasic potassium phosphate, HPLC grade formic acid and
HPLC grade ortho phosphoric acid were purchased from
Merck (Germany). Sodium-1-pentanesulfonate was purchased
from BDH (UK).
2.2. Apparatus
2.2.1. Preparative high performance liquid chromatography
A Shimadzu preparative HPLC equipment with LC-8A pump,
SCL-10A VP system controller, SPD-10AVP UV–VIS detec-
tor, FRC-10A fraction collector and Rheodyne injector with
5.0 mL loop (Make SHIMADZU, Japan) was used. The chro-
matographic separation was achieved on a Gemini C18 (Phe-
nomenex, USA), 150 mm · 30.0 mm, 5 lm semi-preparative
column using a mobile phase containing mixture of water
and acetonitrile (70:30, v/v). The ﬂow rate of the mobile phase
was 20.0 mL/min and the wavelength was monitored at
230 nm. The injection volume was 1.0 mL. The test concentra-
tion for the analysis was 50 mg/mL. Mobile phase was used as
diluent for the preparation of test solutions. The data were re-
corded using LC solution software. The eluent was monitored
at 230 nm and the collected fractions were injected into analyt-
ical HPLC to conﬁrm the retention times. The collected frac-
tions from preparative HPLC were evaporated using a
rotovapor.
2.2.2. High performance liquid chromatography (HPLC)
The HPLC system was equipped with quaternary gradient
pumps, auto-sampler and auto-injector (Model LC2010CHT,
Make SHIMADZU, Japan) connected to photo diode array
detector controlled with LC Solution software (Make SHIMA-
DZU, Japan). A C18 column, of 125 · 4.6 mm, 5 lm (Kroma-
sil) and the mobile phase consist of a mixture of 2.0 g of
monobasic potassium phosphate and 3.8 g of sodium-1-pen-
tanesulfonate in 1000 mL of water, pH at 3.0 with 1 M
phosphoric acid. The eluent was monitored at 230 nm and ata ﬂow rate of 1.0 mL/min. The telmisartan drug substance
was dissolved in mobile phase as diluents and the sample was
sonicated for about 5 min; the sample was further ﬁltered
through 0.2 lm syringe ﬁlter and then injected into HPLC.
2.2.3. Mass spectrometry (MS)
Direct ionization (DI) mass was performed on GCMS-2010
(Shimadzu, Japan) equipped with DI source. Sample was
introduced into the ion source with detector voltage 1.25 kV,
detector temperature 300 C, ion source temperature 225 C
and ionization energy 70 eV. The data were recorded using
GC solution software.
The high resolution mass spectrometer consisted of an
Agilent 1200 series high performance liquid chromatography
system and a micrOTOFQ mass spectrometer (High sensitivity
orthogonal time-of-ﬂight instrument; Bruker Daltonics, Ger-
many). All samples were analyzed in the micrOTOFQ mass
spectrometer equipped with an ESI source for accurate mass
values. In-house compound was used as an internal reference
compound, which was introduced via six port divert valve
using the Hystar and micrOTOF control softwares. The mass
range was calibrated with ESI tuning mix solution (Part no.
G2421A) from Agilent Technologies using quadratic ﬁt. The
sample was dissolved in methanol, sonicated for 10 min and
diluted further to get a concentration of 10 lg/mL. An injec-
tion volume of 5 lL of sample was introduced using an
auto-sampler in the ﬂow injection of 0.1% formic acid solution
in water and acetonitrile (1:1) at a ﬂow rate of 200 lL/min. The
ESI tuning mix solution (1/10) in acetonitrile containing 10 lg/
mL of in-house reference compound was infused via infusion
syringe to ﬁll the 20 lL injection loop on six port divert valve.
Using micrOTOF control software, the elution of sample peak
followed by that of ESI tuning mix was programed.
2.2.4. NMR and IR spectrometry
The 1H, 13C, and DEPT experiments were performed in AL
300 MHz JEOL FT NMR spectrometer. All 2D-NMR
experiments, Correlation Spectroscopy (COSY), Heteronu-
clear Single Quantum Coherence (HSQC) and Heteronuclear
Multiple Bond Coherence (HMBC) were performed using a
gradient probe using CDCl3 solvent in Bruker Avance
500 mHz FT NMR spectrophotometer equipped with 5 mm
1H/13C/X (15N) three-channel triple resonance (TXI) probe,
the pulse program used was employed from the pulse program
library of Bruker. The data obtained were processed and ana-
lyzed by using Bruker software. The 1H chemical shift values
were reported on the d scale in ppm, relative to TMS
(d – 0.00 ppm) and chemical shift values were reported relative
to CDCl3 (d = 77.00 ppm), as internal standards respectively.
The hydrogen and carbon chemical shifts are referred to the
internal tetramethylsilane (TMS). The coupling constants are
expressed in Hertz.
NMR Spectral data of Impurity-1: 1H-NMR (CDCl3,
300 MHz), d (ppm), J (Hz): 3.64 (s, 3H, OCH3), 6.71 (s, 1H,
CHBr2, 7.36–7.38, (d, J= 8.42, 2H, Ar-H), 7.40–7.43 (t,
J= 8.61, 1H, Ar-H), 7.47–7.52 (t, J= 7.69, 1H, Ar-H),
7.58–7.61 (d, J= 6.04, 1H, Ar-H), 7.65–7.68 (d, J= 8.42,
2H, Ar-H) and 7.92–7.95(d, J= 7.69, 1H, Ar-H). 13C-NMR,
d (ppm): 40.77 (–CHBr2, C-1), 51.92 (–OCH3, C-15), 126.18
(–CH, C-7&3), 127.62 (–CH, C-11), 128.56 (–CH, C-6&4),
130.02 (–CH, C-10), 130.57 (–C, C-9), 130.63 (–CH, C-13),
S1518 V. Srinivasan et al.131.42 (–CH, C-12), 140.66 (–C, C-2), 141.37 (–C, C-5), 142.97
(–C, C-8) and 168.55 (C‚O, C-14).
The IR spectra were recorded in the solid state in KBr dis-
persion medium using Perkin–Elmer Spectrum One FT IR
spectrophotometer.
2.2.5. Theoretical methods
The theoretical calculations presented here were performed
with the Gaussian-94/DFT (Pople, 1995) program on a
Pentium (IV) computer system. The molecular geometry of
the impurity was optimized using the HF method with the ba-
sis set 6-31G*.
3. Results and discussion
The isolated impurity was analyzed by HPLC and the HPLC
purity was found to be 97.4%. The analytical HPLC chro-
matograms of telmisartan along with impurities are shown in
(Fig. 1). Telmisartan eluted at a retention time of 14.24 minFigure 1 Typical chromatograms of (a) telmisartaand the impurity at 22.69 min. To get a preliminary structural
insight, mass analysis was carried out on the isolated sample.
The mass spectra obtained showed molecular ions of the impu-
rity at m/z 384[(M)+] whereas the telmisartan displayed molec-
ular ions at m/z 514[(M)+]. Thus impurity has 130 amu less
than that of the molecular ion of telmisartan.
The impurity was separated from telmisartan by preparative
HPLC so as to isolate a larger amount of impurity for suitable
spectroscopic investigation. Analytical HPLC chromatogram
after the isolation of impurity was shown in (Fig. 1). The
NMRdata of the isolated impurity were collected and the struc-
ture of the impurity has been assigned with the help of COSY,
HSQC and HMBC data.
3.1. Structure elucidation of impurity
The isolated impurity was initially analyzed by IR spectrometry
(Fig. 2). The important vibrational signatures are analyzed and
given in Table 1. HR-MS data showed exact mass of the molec-n with all impurities and (b) isolated impurity.
Figure 2 IR spectrum of impurity.
Table 1 FT-IR spectral assignment for impurity.
S. no. Compound IR (KBr) absorption bands (cm1)
1 Impurity 3013(s) C–H stretch,
1714(s) C‚O stretch,
1250(s) C–O stretch
s – strong.
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383.9166) (Calcd. 384.06 for C15H12O2Br2), which corresponds
to the molecular formula C15H12O2Br2. The
1H-NMR data of
impurity were compared with those of telmisartan. The 1H-
NMR spectrum (Fig. 3) has a peak at 3.64 ppm integrating
for 3 protons. The DEPT135 and DEPT90 experiments show
a peak at 52.03 ppmwhich corresponds to –OCH3 group. There
is a singlet at 6.71 ppm which may be an isolated –CH group
since there is no splitting. There are two doublets and two trip-
lets in the aromatic region. This shows that there could be an
ortho substituted phenyl ring present in the moiety. Moreover
there are two doublets integrating for two protons each. This
shows clearly that there is a para-substituted phenyl ring present
in the moiety. This is being assumed based on the couplingconstant values. There are six signals in the aromatic region
of 13C spectrum that correspond to –CH carbons and four qua-
ternary carbons (Fig. 3). Among the six peaks two peaks have
intensities almost double and this could be for four carbons thus
there are eight –CH carbons which matches well with the 1H
integral values of eight –CH groups. It also shows a change in
the chemical shift value of C‚O group which indicates that
there could be a substitution and was not an acid (chemical shift
and coupling constants are given in Section 2).
The HMBC spectrum shows connectivity to –OCH3 to the
carbonyl carbon which comes at 168.55 ppm which generally
indicates the presence of ester function. This carbonyl carbon
shows connectivity to –CH group and another quaternary
carbon. The presence of para and ortho substituted phenyl
rings makes us to believe that it does not have imidazole moi-
ety in this impurity compound. The MS data show that there
are two bromine atoms present in it. From the NMR data it
is clear that no bromine atom is directly attached to phenyl
ring. The presence of –CH group in the aliphatic region of
13C-NMR makes us to believe that both Br atoms are at-
tached to same carbon which was N-methylene in the parent
compound. The 1H and 13C-NMR data show very clearly
that this impurity does not have –CH2 groups which are fur-
ther conﬁrmed by DEPT135 spectrum. All these informations
Figure 3 1H- and 13C-NMR spectra of impurity.
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this impurity molecule. So the remaining moiety in the parent
compound with –CH3 and two bromine atoms should be the
impurity molecule.
The mass data of telmisartan and the impurity were
compared. The data indicate that the molecular ion of telmi-sartan is at m/z 514[(M)+] and the impurity is at m/z
384[(M)+] (Fig. 4) with a characteristic isotopic abundance
for two bromine atoms. The abundance ratio of the molecular
ion is 1:2:1 indicating the presence of two bromines. The imme-
diate fragment of mass m/z 304 accounts for the loss of one
bromine and the abundance ratio of 1:1 indicates the presence
Figure 4 Mass spectrum of impurity.
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Figure 5 Impurity structure with numbering of C atoms.
Figure 6 Optimized structure of the impurity.
Figure 7 Computed IR spectrum of impurity.
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bromines are present in the moiety. The further fragment of
mass m/z 224 indicates a loss of one more bromine and frag-
ment at mass m/z 165 accounts for the loss of –COOCH3
group. The residual mass m/z 152 indicates the presence of
biphenyl ring. Since the moiety is having two bromine groupsand the mass is almost nearer to the mass of one of the inter-
mediate, viz, 40-(bromomethyl) biphenyl-2-carboxylic acid
methyl ester with m/z 305, it is clear that the impurity is related
to the intermediate.
Based on the 2D-NMR and MS data the structure of the
impurity-1 is characterized as ‘‘methyl 4’,40-dibromo methyl
biphenyl-2-carboxylate’’ (Fig. 5).
3.2. Theoretical studies on the impurity
The experimentally arrived structure is further conﬁrmed by
the theoretical calculation. HF level theoretical studies on syn-
thetic route indicative impurity is done. The optimized struc-
ture of the impurity is given in Fig. 6. The computed IR
spectrum is given in Fig. 7. The important vibrational frequen-
cies are assigned with the help of available literature values as
well as from the result of computation.
S1522 V. Srinivasan et al.4. Conclusion
In the present study, an unknown impurity was detected by
HPLC in the drug substance of telmisartan. The source for
the formation of this impurity is from the key starting material
of telmisartan (4-methyl biphenyl-2-carboxylate), which on
bromination with 1,3-dibromo-5,5-dimethyl hydantoin in the
presence of Azobis isobutyro nitrile as a catalyst yields 40-(bro-
momethyl) biphenyl-2-carboxylic acid methyl ester and the
impurity as by product. The attempt to isolate this impurity
has been successful. The impurity was isolated by preparative
HPLC and characterized by spectroscopic studies. The struc-
ture of this impurity was not reported earlier in literature. This
study highlights the importance of impurity proﬁling in a drug
substance.
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